What is the appropriate acute management for a patient with MDMA intoxication?

Acute Management of MDMA Intoxication

Administer benzodiazepines immediately for agitation and seizures, initiate rapid external cooling for hyperthermia >40°C, and use vasodilators (not β-blockers) for persistent hypertension or coronary vasospasm. 1

Initial Assessment and Monitoring

• Institute continuous cardiac monitoring immediately to detect dysrhythmias, tachycardia, or myocardial ischemia from coronary vasospasm. 1
• Measure core temperature promptly; hyperthermia >40°C is rapidly life-threatening and drives multi-organ toxicity including rhabdomyolysis, disseminated intravascular coagulation, and acute renal failure. 1, 2, 3
• Establish intravenous access and prepare for aggressive fluid resuscitation, particularly if rhabdomyolysis develops. 3

Benzodiazepine Sedation (First-Line for Multiple Complications)

• Administer benzodiazepines without delay for severe agitation, psychomotor excitation, or seizures; they are the cornerstone of MDMA toxicity management. 1
• Titrate to effect using large doses if needed (e.g., lorazepam 2–4 mg IV every 5–10 min or diazepam 5–10 mg IV) until adequate sedation is achieved. 1
• Benzodiazepines control agitation, lower heat production, prevent rhabdomyolysis progression, terminate seizures, and often normalize sympathomimetic-induced hypertension and tachycardia. 1, 4

Hyperthermia Management (Class I Priority)

• Initiate rapid external cooling immediately for core temperature >40°C or any patient with altered mental status and elevated temperature. 1
• Use evaporative cooling (mist + fan) or ice-water immersion, which are significantly more effective than cooling blankets, ice packs, or endovascular devices. 1
• Target normothermia (≈37°C) as quickly as possible; continue cooling until core temperature reaches 38.5°C, then monitor closely for rebound hyperthermia. 1
• Dantrolene is NOT recommended despite historical use; a 2022 case series showed it did not reduce end-organ damage in MDMA-induced hyperpyrexia, and degree of organ injury correlates primarily with initial core temperature rather than dantrolene administration. 5

Cardiovascular Management

Hypertension and Tachycardia

• Benzodiazepine sedation is first-line therapy for sympathomimetic-induced hypertension and tachycardia; adequate sedation often normalizes vital signs without additional agents. 1
• If hypertension persists despite adequate sedation, add vasodilators such as phentolamine (α-blocker, 2.5–5 mg IV) or nitroglycerin infusion. 1
• β-blockers are absolutely contraindicated; unopposed α-adrenergic stimulation can worsen hypertension and precipitate coronary vasospasm. 1

Coronary Vasospasm and Myocardial Ischemia

• Administer vasodilators immediately (phentolamine 2.5–5 mg IV or nitroglycerin infusion) for chest pain, ST-segment changes, or troponin elevation suggestive of coronary vasospasm. 1
• Benzodiazepines may reverse vasospasm by reducing sympathetic tone and should be given concurrently. 1

Cardiogenic Shock and Cardiac Arrest

• Consider mechanical circulatory support early (intra-aortic balloon pump or veno-arterial ECMO) for refractory cardiogenic shock unresponsive to fluid resuscitation and vasopressors. 1
• MDMA-induced stress (takotsubo) cardiomyopathy is often reversible with days-to-weeks of circulatory support; early ECMO consultation improves outcomes. 1, 6
• Veno-arterial ECMO is a reasonable rescue therapy for refractory cardiac arrest while toxicity resolves (Class IIa recommendation). 1

Rhabdomyolysis Management

• Aggressive intravenous fluid resuscitation (up to 5 L/day) is essential to enhance myoglobin elimination and prevent acute renal failure. 3
• Monitor creatine kinase, myoglobin, electrolytes, and renal function closely; MDMA can cause profound rhabdomyolysis (CK >160,000 U/L) even without hyperthermia in susceptible individuals. 7
• Hemodialysis may be necessary for severe acute kidney injury despite aggressive hydration. 3

Critical Pitfalls to Avoid

• Prolonged physical restraints without adequate sedation are potentially lethal, increasing heat production, worsening rhabdomyolysis, and aggravating agitation; restraints must be removed as soon as the patient is adequately sedated. 1
• Never administer β-blockers for hypertension or tachycardia; they worsen outcomes through unopposed α-adrenergic effects. 1
• Do not rely on dantrolene as a primary hyperthermia treatment; rapid external cooling and benzodiazepines are more effective. 5

Supportive Care and Monitoring

• Correct electrolyte abnormalities promptly, particularly hyponatremia (from SIADH and excessive water intake) and hyperkalemia (from rhabdomyolysis). 2
• Monitor for disseminated intravascular coagulation (DIC) and treat with antithrombin III, fresh frozen plasma, and prothrombin complex concentrates as indicated by laboratory parameters. 3
• Maintain normothermia after initial cooling; hyperthermia worsens all aspects of MDMA toxicity. 1